Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 840.00p 839.00p 840.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 215.4 3,254

Btg Share Discussion Threads

Showing 4951 to 4972 of 6225 messages
Chat Pages: Latest  201  200  199  198  197  196  195  194  193  192  191  190  Older
DateSubjectAuthorDiscuss
07/11/2017
02:58
£9 a share they can have it.
bargainbob
06/11/2017
23:36
£12 a share and they can have it!
fhmktg
06/11/2017
17:19
Very poor show today. And these people pay themselves millions, and can't perform. This is not a one off, many millions down the drain in previous news flow, all home grown. I am afraid to have to inform you all that BTG is probably better off in foreign hands, we just don't seem to have the capacity for big business.
cockneytrader
06/11/2017
13:37
I am being writing here many years , that Dame and her Rolf just not good enough and should go. Penalty paid for Biocompatibles, wrong management build own sales Varethena team instead of licence or partner with big ones.Vistogard - lost deal. Although for today move is to blame insiders, who over bought on insiders news and sold of today scared to death .
a1ord53
06/11/2017
13:00
Investor Chronicle just posted update after this mornings announcements stating they believe shares undervalued and are stil buyers.!!
ugandalad
06/11/2017
12:23
I think the company has said there are approx 750k below the knee treatments in US. At $1.6k a treatment that's a market that's worth $1.2bn. So to be a $100m rev biz Varathena would need a 10% market share.
allonblack
06/11/2017
12:18
Allonblack, I take you use the product?
cockneytrader
06/11/2017
12:08
Max dosage is not a guide to how much gets used and shelf life is irrelevant. Typically the doctor will use 3-5ml and that's it. The can gets used over the day on several patients. 15ml would be used very rarely for above the knee main vein. The numbers you are quoting aren't relevant to the news this morning. Varithena may not succeed. But it will be doctors preferring laser treatment to foam. It will have nothing to do with the cost of the can or its shelf life.
allonblack
06/11/2017
11:59
The maximum number of treatments from one canister, in best case is 15 treatments at 3ml minimum uptake. In these clinics Varithena may be an option.
cockneytrader
06/11/2017
11:39
Varithena has never been up and running. Look at the pitiful revenues. One canister contains 45 ml of usable foam of which 15ml is the maximum permissible for one vein. Therefore one canister per three veins. That's $1000 of foam per treatment excluding all other costs. And btw, the canister has only a 30 day shelf life. Varithena has cost shareholders over £250 million to date and is most definitely not up and running.
cockneytrader
06/11/2017
11:19
Varithena is up and running again. I'm not sure where you get the view that its now a write off.Most treatments eg below the knee only need 2/3ml. Most people can be treated in this bracket. The issue is now whether Drs treat using laser or foam not Varithena specific. In fact doctors now have an incentive to use Varithena vs own foam as the fee is 10x higher. Varithena is now more likely to be a 100m biz again as a result of this pricing and def not a write off. The loss of Vistogard is a 2% downgrade to 2020 earnings that was priced in September. Right reaction is probably -4% today after +4% Friday and then higher.
allonblack
06/11/2017
10:54
It was said that to gain growth it needed a joint partnership. Louise will learn her lesson , just because you have a better mouse trap does not mean people will follow your path.
bargainbob
06/11/2017
10:43
Apparently Welstat's complaint was that the sales team was too small to be effective. The Judge agreed. Maybe this is also the problem with the varicose vein treatment.
gregsc
06/11/2017
10:22
Suspect the code pricing is based upon per procedure
gregmorg
06/11/2017
10:13
Next Tuesday should give more insight with reporting and Q andA session. Until then we are just guessing.
bill hunt
06/11/2017
10:00
Though the news is old, but same one, hxxp://www.proactiveinvestors.co.uk/companies/news/184282/btg-shares-fall-as-its-ordered-to-pay-us558mln-in-damages-in-drug-distrubution-dispute-184282.html still price at 900p from Numis Securities
ashehzi
06/11/2017
10:00
The cost of treatment is approx $1500-3000 per procedure. Costs met by the insurer come in at the lower end. If the numbers of treatments don't grow significantly at any time soon, they will have to write Varithena off. Btg are fully valued for now. The loss of the Welstat revenue, several million per year, and was growing. The loss millions from Lemtrada coming off patent. This is not a good news day and £55 million to cough up. I am surprised the market has been so kind.
cockneytrader
06/11/2017
09:51
Noted on Codes, but my question is on the application of payment for multiple veins. Are these rules applicable to multiple veins in the same leg or does it actually apply across both legs? Previous suggested Varithena pricing policies, that I have been aware of, have been on the basis of a single leg and, for all sorts of medical reasons, only one leg could be treated at a time/session with a break of some weeks-if not months before the other leg could be treated. Each leg had been regarded as a separate medical event! So does the Code pricing structure adhere to this one leg principle or does multiple vein treatment actually apply across both legs?
gregmorg
06/11/2017
09:42
Is a treatment , one leg at a time . Could make a big difference on how you read the update. 4 legs can you help lol.
bargainbob
06/11/2017
09:11
It almost like Louise wants the price to be under a certain level . Shocking update on the codes , we will just need to wait till 2018 to see the impact . I suggest getting rid of her to save the time.
bargainbob
06/11/2017
08:44
good to see it recovering back
ashehzi
06/11/2017
08:14
At least this should accelerate growth in Varithena - $3000 against a brick wall is not smart.
weatherman
Chat Pages: Latest  201  200  199  198  197  196  195  194  193  192  191  190  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 01:40:01